863329-66-2 Usage
Description
2'-deoxy-2'-fluoro-2'-C-methyluridine, also known as (2'R)-2'-Deoxy-2'-fluoro-2'-methyluridine or PSI-6206, is a deaminated metabolite of β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine. It is a nucleoside analog that has been found to be an effective inhibitor of hepatitis C virus (HCV) RNA polymerase.
Uses
Used in Antiviral Applications:
2'-deoxy-2'-fluoro-2'-C-methyluridine is used as an antiviral agent for the treatment of hepatitis C virus (HCV) infections. It works by inhibiting the HCV RNA polymerase, thereby suppressing the replication of the virus and reducing viral load in infected individuals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2'-deoxy-2'-fluoro-2'-C-methyluridine is used as a key intermediate in the synthesis of antiviral drugs targeting hepatitis C virus. Its unique structure allows for the development of more effective and targeted therapies against the virus, potentially leading to improved treatment outcomes for patients suffering from HCV infections.
Biological Activity
psi-6206 (as known as ro-2433 or gs-331007), β-d-2’-deoxy-2’-fluoro-2’-c-methyluridine, is the deaminated derivative of psi-6130, β-d-2’-deoxy-2’-fluoro-2’-c-methylcytidine, which is a potent inhibitor of hepatitis c virus (hcv) replication in the subgenomic hcv reolicon system. psi-6206, itself, does not shown any inhibitory activity towards hcv replication in the hcv subgenomic replicon system. however, the its triphosphate form, ro2433-tp, is a potent inhibitor of rna synthesis by hcv polymerase, which inhibits both the rna sysnthesis activity of hcv replicase (ic50 = 1.19 um) and the rna synthesis activity of the recombinant hcv con1 ns58 on a heteropolymeric rna template derived from the 3’-end of the negative strand of the hcv genome (ic50 = 0.52 um and ki = 0.141 um).han ma, wen-rong jiang, nicole robledo, vincent leveque, samir ali, teresa lara-jamie, mohammad masjedizadeh, david b. smith, nick cammack, klaus klumpp, and julian symons. characterization of the metabolic ctivation of hepatitis c virus nucleoside inhibitor β-d-2’-deoxy-2’-fluoro-2’-c-methylcytidine (psi-6130) and identification of a novel active 5’-triphosphate species. the journal of biological chemistry 2007; 282(41): 29812-29820
Check Digit Verification of cas no
The CAS Registry Mumber 863329-66-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,3,3,2 and 9 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 863329-66:
(8*8)+(7*6)+(6*3)+(5*3)+(4*2)+(3*9)+(2*6)+(1*6)=192
192 % 10 = 2
So 863329-66-2 is a valid CAS Registry Number.
863329-66-2Relevant articles and documents
Preparation method of intermediate
-
Paragraph 0030-0035; 0040-0043, (2021/09/08)
The invention relates to the field of pharmacy, in particular to a preparation method of an intermediate of a solovir intermediate (2 ’ R) -2 ’ - deoxidized -2 ’ -fluoro -2 ’ -methyl urea, and a compound represented by the formula II is reacted with triethylamine/methanol to generate a dehydroxylation protection reaction. By adopting the technical scheme disclosed by the invention, the total yield is high, the purity of the target product is high, the product stability is good, and the method is suitable for large-scale production. , Due to the fact that the adopted raw material cost is low, the process conditions are mild and non-rigorous, the method is easy to operate and easy to popularize.
Preparation method of sofosbuvir key intermediate
-
Paragraph 0013, (2020/05/01)
The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a sofosbuvir key intermediate. The preparation method of the sofosbuvir intermediate hasthe advantages of short reaction steps, mild reaction conditions and higher yield than that of an existing preparation method, is economical and effective, and is suitable for large-scale industrial production.
AN IMPROVED PROCESS FOR THE PREPARATION OF SOFOSBUVIR
-
, (2018/02/20)
The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of Sofosbuvir. The present invention involves use of reagents that are less expensive, easier to handle and eco-friendly process.